Allucent Launches Decentralized Clinical Trial Solution
Allucent announced that it has partnered with THREAD to launch Allucent Patient Direct Trials. The new offering brings technology, development, and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial (DCT) approaches that address their needs.
Allucent Patient Direct Trials leverages this experience to address the needs of many small and emerging biotech companies that may not have the in-house resources required to design and oversee DCTs. Working with THREAD, Allucent's team of regulatory and product development consultants can guide sponsors in determining the most effective and efficient digital strategies for remote engagement and data collection for their studies.
Reference
Allucent Launches Decentralized Clinical Trial Solution at 2023 World Orphan Drug Congress. (2023, May 23). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
